На этой странице перечислены больницы направления «Трансплантация печени и гепатобилиарная хирургия» (включая Lung Transplant) в Ченнаи, Индия, включая Apollo Hospitals, Greams Road, Gleneagles Global Hospital, Dr. Rela Institute and Medical Centre, SIMS Hospital и другие.
Спросите нас о «Lung Transplant» в Ченнаи, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 8 аккредитованных больниц (Трансплантация печени и гепатобилиарная хирургия) в Ченнаи, Индия
Рекомендуем🇮🇳 Apollo Hospitals, Greams Road
Больница занимает 1-е место в этом списке по указанному рейтингу (4.7/5, 125 отзывов).
🇮🇳 Gleneagles Global Hospital
Больница занимает 2-е место в этом списке по указанному рейтингу (4.7/5, 112 отзывов).
🇮🇳 Dr. Rela Institute and Medical Centre
Больница занимает 3-е место в этом списке по указанному рейтингу (4.7/5, 108 отзывов).
🇮🇳 SIMS Hospital
Больница занимает 4-е место в этом списке по указанному рейтингу (4.6/5, 20 отзывов).
🇮🇳 Sankara Nethralaya
Больница занимает 5-е место в этом списке по указанному рейтингу (4.4/5, 220 отзывов).
🇮🇳 Apollo First Med Hospitals, Kilpauk
Больница занимает 6-е место в этом списке по указанному рейтингу (4.4/5, 76 отзывов).
🇮🇳 MIOT International
Больница занимает 7-е место в этом списке по указанному рейтингу (4.4/5, 200 отзывов).
🇮🇳 MGM Healthcare
Больница занимает 8-е место в этом списке по указанному рейтингу (3.7/5, 34 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Трансплантация печени и гепатобилиарная хирургия» указано среди её специализаций и она находится в Ченнаи, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «lung transplant» в Ченнаи, Индия?
Выбор подходящей больницы для «lung transplant» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Трансплантация печени и гепатобилиарная хирургия», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Lung Transplant»
A lung transplant is a life-saving surgical procedure in which one or both diseased lungs are replaced with healthy donor lungs, indicated for end-stage pulmonary conditions such as idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), cystic fibrosis, and pulmonary arterial hypertension. Leading transplant centers in India and the UAE report one-year survival rates of 80–88% and five-year survival rates of 50–60%, consistent with international benchmarks published by the International Society for Heart and Lung Transplantation (ISHLT). GAF Healthcare connects international patients with JCI- and NABH-accredited centers in India and JCI- and DHA-licensed hospitals in Dubai and Abu Dhabi, providing end-to-end coordination from donor matching logistics to post-transplant immunosuppression management. Hospital Stay: 25–40 days (ICU: 7–14 days; step-down ward: 18–26 days) • Total Stay in Country (Fit-to-Fly): 10–16 weeks post-transplant (subject to pulmonary function testing, absence of acute rejection episodes, and treating physician clearance) • Success Rate: 80–88% (one-year survival); 50–60% (five-year survival) per ISHLT 2023 registry data
Clinical Overview
End-stage lung disease represents irreversible, progressive destruction of pulmonary parenchyma or vasculature that renders conventional medical therapy ineffective. In conditions such as idiopathic pulmonary fibrosis (IPF), the alveolar architecture is replaced by fibrotic scar tissue, precipitating a catastrophic decline in diffusion capacity (DLCO) and forced vital capacity (FVC). In COPD and emphysema, hyperinflation and bullous destruction eliminate effective gas exchange surface area. Pulmonary arterial hypertension (PAH) imposes extreme afterload on the right ventricle, frequently culminating in right heart failure. These pathophysiological cascades converge on a shared endpoint: refractory hypoxia, exercise intolerance, and death without transplantation. Lung transplantation replaces the failed organ with a cadaveric donor allograft, restoring near-normal ventilatory mechanics and gas exchange. The procedure may involve a single-lung transplant (SLT), bilateral sequential lung transplant (BSLT — now the predominant global approach), or heart-lung transplant (HLT) for combined cardiopulmonary failure. The surgical team anastomoses the bronchus, pulmonary artery, and pulmonary veins (or left atrial cuff) of the donor lung to the recipient. Post-operatively, lifelong immunosuppressive therapy — typically a calcineurin inhibitor (tacrolimus or cyclosporine), an antiproliferative agent (mycophenolate mofetil or azathioprine), and a corticosteroid — prevents allograft rejection. The standard of care at high-volume centers in India and the UAE aligns with ISHLT guidelines and incorporates advanced donor lung preservation using Perfadex-LLP solution, ex vivo lung perfusion (EVLP) technology to assess and recondition marginal donor lungs, intraoperative extracorporeal membrane oxygenation (ECMO) support instead of traditional cardiopulmonary bypass (CPB), and multidisciplinary transplant committees for post-operative management. Lung allocation in India is governed by the National Organ and Tissue Transplant Organisation (NOTTO) under the Transplantation of Human Organs and Tissues Act (THOTA), while the UAE operates under the Dubai Health Authority (DHA) and Ministry of Health and Prevention (MoHAP) regulatory frameworks.
Who is a Candidate?
• ELIGIBLE CONDITIONS: End-stage COPD/emphysema (FEV1 < 20% predicted with homogeneous distribution or DLCO < 20%), idiopathic pulmonary fibrosis (FVC < 80% or DLCO < 40% with 10% decline over 6 months), cystic fibrosis (FEV1 < 30% predicted), pulmonary arterial hypertension refractory to prostacyclin therapy, bronchiectasis, sarcoidosis, lymphangioleiomyomatosis (LAM), and re-transplantation for chronic lung allograft dysfunction (CLAD/BOS). • FUNCTIONAL ELIGIBILITY CRITERIA: NYHA/WHO functional class III–IV; resting or exertional oxygen dependence; significant functional limitation despite maximal medical therapy; estimated 2-year mortality > 50% without transplant (assessed using disease-specific risk scores such as the BODE index for COPD or the GAP model for IPF). • REQUIRED DIAGNOSTIC WORKUP (PRE-TRANSPLANT EVALUATION): High-resolution CT (HRCT) chest, full pulmonary function tests (spirometry, body plethysmography, DLCO), 6-minute walk test (6MWT), right heart catheterization, transthoracic echocardiography (TTE/ECHO) with Doppler, coronary angiography (patients > 40 years or with cardiac risk factors), V/Q scintigraphy, arterial blood gas (ABG) analysis, complete metabolic panel, renal and hepatic function tests, HLA typing and crossmatch, CMV/EBV/HIV/HBV/HCV serology, bone density scan (DEXA), and psychosocial assessment. • ABSOLUTE CONTRAINDICATIONS: Active malignancy within the past 2 years (excluding non-melanoma skin cancers), severe non-pulmonary organ dysfunction (renal GFR < 40 mL/min, hepatic cirrhosis, significant coronary artery disease not amenable to revascularization), active extrapulmonary infection including tuberculosis, documented non-adherence to medical regimens, active tobacco/substance use within 6 months, and uncontrolled psychiatric illness. • RELATIVE CONTRAINDICATIONS: Age > 65 years (SLT) or > 60 years (BSLT) is not absolute but increases risk stratification; severe osteoporosis; BMI > 35 or < 17 kg/m²; mechanical ventilation or ECMO dependency prior to listing increases urgency and risk; prior pleurodesis or thoracic surgeries (increases technical complexity).
Treatment Options & Approaches
BILATERAL SEQUENTIAL LUNG TRANSPLANT (BSLT — GOLD STANDARD): The preferred technique for most diagnoses including COPD, CF, and PAH. The recipient undergoes sequential replacement of each lung through a clamshell (bilateral anterolateral thoracotomy) or bilateral thoracosternotomy incision. Each bronchial, pulmonary artery, and pulmonary vein anastomosis is completed individually. ECMO (venoarterial or venovenous) is the preferred circulatory support modality over traditional cardiopulmonary bypass, as it is associated with lower rates of primary graft dysfunction (PGD) and improved coagulation profiles. BSLT yields superior long-term survival and is now performed in over 75% of all lung transplants globally. SINGLE-LUNG TRANSPLANT (SLT): Indicated primarily for IPF and selected COPD patients. Performed via a standard posterolateral thoracotomy. SLT carries shorter operative time and reduced donor organ demand but is associated with greater ventilation-perfusion mismatch and lower long-term survival compared to BSLT. The technique is less suitable for septic lung diseases (CF, bronchiectasis) where the native lung could contaminate the allograft. HEART-LUNG TRANSPLANT (HLT): Reserved for Eisenmenger syndrome, end-stage PAH with biventricular failure, and complex congenital heart disease with pulmonary hypertension. Requires total cardiopulmonary bypass and en-bloc implantation of the donor heart and lungs. Performed at select high-volume centers in India (Chennai, Mumbai) and the UAE (Cleveland Clinic Abu Dhabi). EX VIVO LUNG PERFUSION (EVLP): A groundbreaking organ reconditioning technology (Vivoline LS1 or XVIVO Perfusion System) that allows surgeons to assess and repair marginal or declined donor lungs outside the body using a normothermic perfusion circuit. EVLP can expand the usable donor pool by 20–30% and is now offered at advanced transplant programs in India and the UAE, significantly reducing waitlist mortality. INTRAOPERATIVE ECMO: Modern transplant programs have shifted from conventional CPB to ECMO (Maquet Cardiohelp, LivaNova) for circulatory support during transplantation. ECMO offers superior lung protection, fewer systemic inflammatory responses, reduced blood product utilization, and the ability to transition seamlessly to post-operative support if primary graft dysfunction occurs. IMMUNOSUPPRESSION PROTOCOLS: Modern triple-drug maintenance regimens include tacrolimus (target trough 10–15 ng/mL in the first year), mycophenolate mofetil (MMF) 1,000–1,500 mg twice daily, and prednisolone with planned tapering. Induction agents such as basiliximab (IL-2 receptor antagonist) or anti-thymocyte globulin (ATG) are used perioperatively to reduce early rejection risk. mTOR inhibitors (sirolimus, everolimus) may replace CNIs in select patients for renal preservation or management of chronic lung allograft dysfunction (CLAD). ACUTE REJECTION MANAGEMENT: Acute cellular rejection (ACR) is classified per ISHLT grading (A0–A4) on transbronchial biopsy. Grade A2 and above is treated with high-dose IV methylprednisolone (500–1,000 mg × 3 days). Antibody-mediated rejection (AMR) is managed with plasmapheresis, IV immunoglobulin (IVIG), and rituximab. Chronic lung allograft dysfunction (CLAD), including bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS), remains the leading cause of late mortality and is managed with azithromycin, montelukast, extracorporeal photopheresis (ECP), and where appropriate, re-transplantation.
Восстановление
PHASE 1 — REMOTE PRE-EVALUATION (WEEKS 1–3): GAF Healthcare coordinates the transfer of all prior medical records, imaging (HRCT, PFTs, ECHO, right heart catheterization), and laboratory results to the chosen transplant center. The transplant pulmonologist and cardiothoracic surgeon conduct a telemedicine consultation to determine candidacy and provisional listing status. A detailed cost estimate and logistical plan are provided. PHASE 2 — IN-COUNTRY PRE-TRANSPLANT EVALUATION (DAYS 1–7 AFTER ARRIVAL): Upon arrival, the patient undergoes a comprehensive in-person evaluation including repeat pulmonary function testing, 6-minute walk test, echocardiography, coronary angiography (if indicated), HLA typing and donor-specific antibody (DSA) panel-reactive antibody (PRA) testing, CT chest with contrast, and full metabolic and infectious disease screening. The multidisciplinary transplant committee convenes to confirm listing and assign waitlist status per NOTTO (India) or MoHAP/DHA (UAE) protocols. PHASE 3 — WAITING PERIOD & DONOR MATCHING: Waiting time varies significantly and is unpredictable, ranging from days to several months. GAF Healthcare arranges suitable local accommodation for the patient and attendant. The transplant team maintains the patient in optimal medical condition through pulmonary rehabilitation, optimization of nutritional status, and management of comorbidities. Patients may be bridged with supplemental oxygen, non-invasive ventilation (NIV/BiPAP), or in urgent cases, ECMO as a bridge to transplant (BTT). PHASE 4 — TRANSPLANT SURGERY (OPERATIVE DAY): Upon donor organ availability and confirmation of acceptable cold ischemic time (ideally < 6 hours for bilateral lungs), the patient is admitted urgently and prepared for surgery. The operative procedure (BSLT, SLT, or HLT) typically takes 6–12 hours under general anesthesia with intraoperative ECMO or CPB support. The surgical team performs bronchial, pulmonary artery, and pulmonary vein (or left atrial cuff) anastomoses under meticulous tension-free technique. Bronchial anastomotic integrity is assessed with intraoperative bronchoscopy. PHASE 5 — ICU & ACUTE POST-OPERATIVE CARE (DAYS 1–14): The patient is managed in the cardiothoracic ICU with mechanical ventilation (targeted to early extubation within 24–48 hours where possible), continuous hemodynamic monitoring, ECMO weaning protocols, immunosuppression initiation, anti-infective prophylaxis (trimethoprim-sulfamethoxazole for PCP, valganciclovir for CMV, fluconazole/voriconazole for fungal prophylaxis), and daily surveillance bronchoscopies with BAL cultures. Primary graft dysfunction (PGD) is graded per ISHLT criteria and managed with lung-protective ventilation, prone positioning, and ECMO if grade PGD 3. PHASE 6 — STEP-DOWN WARD & REHABILITATION (DAYS 14–40): Transition from ICU to a specialized thoracic step-down unit. Progressive chest physiotherapy, incentive spirometry, and supervised pulmonary rehabilitation commence. Surveillance transbronchial biopsies are performed at weeks 3, 6, and 12 post-transplant to detect subclinical rejection. Tacrolimus and MMF dosing is optimized based on trough levels and renal function. Discharge planning begins, with patient and caregiver education on home spirometry monitoring (FEV1/FVC diary), medication schedules, and rejection/infection symptom recognition. PHASE 7 — POST-DISCHARGE OUTPATIENT FOLLOW-UP (WEEKS 6–16): Weekly outpatient clinic visits at the transplant center for the first 6–8 weeks post-discharge, covering pulmonary function monitoring, drug level testing, chest X-rays, and bronchoscopy as indicated. The fit-to-fly assessment incorporates: stable or improving FEV1 (> 50% predicted), no active rejection or infection, oxygen independence at rest and with ambulation, and physician sign-off on fitness for long-haul travel (minimum 10–16 weeks post-transplant for intercontinental flights). GAF Healthcare coordinates all follow-up appointments and the transition to the patient's home country pulmonologist with a full medical handover package.
Возможные риски
Lung transplantation carries significant perioperative and long-term risks that every patient must understand before proceeding. Primary graft dysfunction (PGD), a form of ischemia-reperfusion injury affecting the donor lung within 72 hours of transplant, occurs in up to 25% of recipients and is the leading cause of early mortality; severe PGD (Grade 3) may require ECMO support and carries a 30-day mortality of 40–50%. Acute cellular rejection (ACR) affects approximately 30–50% of recipients in the first year and is managed with high-dose steroids, though recurrent ACR accelerates progression to chronic allograft dysfunction. Antibody-mediated rejection (AMR) is increasingly recognized and more difficult to treat than ACR. Airway anastomotic complications — including bronchial stenosis, dehiscence, and bronchomalacia — occur in 5–15% of cases and may require bronchoscopic interventions (balloon dilation, endobronchial stenting, or laser therapy). Infectious complications are the leading cause of death after the first month, with bacterial pneumonia, CMV pneumonitis, Aspergillus infections, and Pneumocystis jirovecii pneumonia being the most clinically significant; recipients are maintained on lifelong anti-infective prophylaxis and monitored with serial BAL cultures and serum CMV PCR. Calcineurin inhibitor-related nephrotoxicity (tacrolimus, cyclosporine) causes chronic kidney disease in up to 30% of five-year survivors, occasionally necessitating renal replacement therapy. Chronic lung allograft dysfunction (CLAD), encompassing bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS), affects over 50% of recipients by five years and is the dominant cause of late mortality, with no reliably curative treatment. Additional long-term risks include post-transplant lymphoproliferative disorder (PTLD), metabolic complications of immunosuppression (new-onset diabetes, hypertension, hyperlipidemia, osteoporosis), and increased susceptibility to non-melanoma skin malignancies. Operative mortality at high-volume centers in India and the UAE ranges from 5–10% for elective cases.
Почему GAF Healthcare
GAF Healthcare provides a seamlessly coordinated non-medical support infrastructure designed to eliminate logistical friction for international patients undergoing lung transplantation in India or the UAE. INDIA — E-MEDICAL VISA & ENTRY: GAF Healthcare facilitates the Indian e-Medical Visa application through the Government of India's e-Visa portal (indianvisaonline.gov.in). The e-Medical Visa permits a stay of up to 60 days (extendable up to 180 days for transplant patients) and allows up to two accompanying attendants on e-Medical Attendant Visas. GAF prepares and reviews all required documents including the hospital invitation letter, diagnostic reports, and financial proof to maximize visa approval probability and minimize processing delays. UAE — VISA & ENTRY: Citizens of over 120 countries receive visa-on-arrival or visa-free access to the UAE for 30–90 days. For patients requiring extended stays of 3–4 months for transplant and immediate follow-up, GAF Healthcare coordinates long-term medical residency visa applications through the Dubai Health Authority (DHA) patient visa pathway or Abu Dhabi Health Services (SEHA) medical travel program, ensuring legal residency throughout the treatment episode. AIRPORT TRANSFERS & GROUND LOGISTICS: Dedicated GAF Healthcare case managers arrange medically equipped airport transfers (including oxygen-equipped vehicles for respiratory patients), inter-facility transfers between diagnostic centers and transplant hospitals, and emergency ground transport if required during the waitlist period. DEDICATED MEDICAL INTERPRETERS: Professional medical interpreters fluent in Arabic, Russian, French, Swahili, Bangla, and over 20 languages are on call 24/7 to facilitate patient-physician communication during consultations, consent processes, and family meetings, ensuring zero communication gaps in high-stakes clinical discussions. ATTENDANT ACCOMMODATION: Given the 10–16 week total country stay for lung transplant recipients, GAF Healthcare arranges serviced apartments, hotel accommodations, or hospital guest houses within close proximity to the transplant center for the patient's family or attendant. Options range from budget-conscious ($30–60/night in India) to premium serviced apartments ($100–250/night in Dubai/Abu Dhabi). CONTINUITY OF CARE & MEDICAL HANDOVER: Upon discharge and fit-to-fly clearance, GAF Healthcare prepares a comprehensive medical handover package — including operative reports, immunosuppression protocols, surveillance bronchoscopy results, and a 12-month monitoring schedule — transmitted to the patient's home country pulmonologist or transplant physician to ensure uninterrupted post-transplant care.
Частые вопросы о процедуре «Lung Transplant»
What is the cost of a lung transplant in India versus the UAE?
How long do I need to stay in the country before I am fit to fly home after a lung transplant?
What is the success rate of a lung transplant?
Как GAF Healthcare помогает выбрать лучшую больницу для «lung transplant» в Ченнаи, Индия
Найдите лучшие больницы для «lung transplant» в Ченнаи, Индия
На этой странице представлено 8 больниц в Ченнаи, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Lung Transplant» в Ченнаи, Индия
Сколько больниц направления «Трансплантация печени и гепатобилиарная хирургия» представлено в Ченнаи, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Ченнаи, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Lung Transplant» в Ченнаи, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.